Last updated: August 7, 2026
Succinylcholine chloride is an established injectable neuromuscular blocker with limited active-ingredient patent protection and low formulation complexity. Commercial value is concentrated in manufacturing reliability, preservative-free presentation, pediatric safety, ready-to-use packaging, cold-chain performance, and hospital supply continuity rather than in new chemical-entity exclusivity.
The strongest product opportunities are:
- Preservative-free single-dose vials and prefilled syringes
- Concentration-specific products for rapid-sequence intubation and operating-room use
- Reduced-error packaging with clear differentiation between 20 mg/mL and 100 mg/mL presentations
- Improved cold-chain and in-use stability
- Contract manufacturing and shortage-resilient supply
- Hospital-specific presentations that reduce dilution, preparation, and medication-error risk
Succinylcholine chloride is an old small-molecule injectable. The commercial barrier is regulatory execution and supply quality, not patent ownership.
What is the FDA status of succinylcholine chloride injection?
Succinylcholine chloride injection is FDA-approved for short-term skeletal-muscle paralysis during anesthesia, endotracheal intubation, and mechanical ventilation. It is administered intravenously or intramuscularly and is used primarily in hospitals, emergency departments, ambulances, and procedural centers.
The drug is a depolarizing neuromuscular blocker. Its rapid onset and short duration make it useful when airway control is urgent. The FDA labeling identifies risks including hyperkalemia, malignant hyperthermia, bradycardia, prolonged paralysis, and anaphylaxis. It is not interchangeable clinically with nondepolarizing agents such as rocuronium, even though both are used for neuromuscular blockade. (U.S. Food and Drug Administration [FDA], 2023a)
Key clinical and formulation parameters
| Parameter |
Typical product or label position |
| Active ingredient |
Succinylcholine chloride |
| Common concentrations |
20 mg/mL and 100 mg/mL |
| Routes |
Intravenous and intramuscular |
| Adult IV dose for intubation |
Approximately 0.6 mg/kg, adjusted clinically |
| Adult IM dose |
Approximately 3 to 4 mg/kg, with a labeled maximum commonly stated at 150 mg |
| Onset |
Approximately 30 to 60 seconds intravenously |
| Duration |
Approximately 4 to 6 minutes after a typical IV dose |
| Storage |
Refrigerated storage is commonly specified |
| Primary setting |
Hospital and emergency airway management |
| Regulatory category |
Generic injectable drug products and reference-listed products |
The exact inactive ingredients, concentration, container, storage period, and preservative status depend on the manufacturer and presentation. FDA-approved labeling must control product-specific claims. (FDA, 2023a; DailyMed, 2024a)
What excipients are used in succinylcholine chloride injection?
The core formulation is an aqueous solution containing succinylcholine chloride, water for injection, sodium chloride in some presentations, and pH-adjusting agents. Some multidose products contain benzyl alcohol as a preservative. Other products are preservative-free.
A typical formulation strategy includes:
| Formulation component |
Commercial purpose |
Key development issue |
| Water for injection |
Primary vehicle |
Sterility, endotoxin, particulate control |
| Sodium chloride |
Isotonicity adjustment |
Osmolality and compatibility |
| Hydrochloric acid or sodium hydroxide |
pH adjustment |
Stability and injection tolerability |
| Benzyl alcohol |
Preservative in selected multidose products |
Pediatric and neonatal exposure concerns |
| Container-closure system |
Product protection and delivery |
Extractables, leachables, adsorption, breakage |
| Nitrogen or controlled headspace |
Oxidation-control strategy where justified |
Container-process validation |
The formulation is generally not an appropriate target for complex excipient innovation. Succinylcholine chloride is highly water-soluble, and the product is administered in urgent clinical settings. Unnecessary excipients can increase regulatory burden, compatibility risk, and medication-use complexity.
Is benzyl alcohol commercially attractive or risky?
Benzyl alcohol can support a multidose presentation, but its use creates a label and market-access disadvantage for neonatal and certain pediatric applications. FDA labeling warns that benzyl alcohol-containing products should be used carefully in neonates and low-birth-weight infants because of toxicity concerns associated with preservative exposure. (FDA, 2023a)
A preservative-free product has several commercial advantages:
- Broader use in pediatric hospitals
- Lower concern about cumulative preservative exposure
- Easier formulary positioning
- Better suitability for emergency carts and anesthesia departments
- Reduced need for preservative-specific warnings
The tradeoff is that a preservative-free product generally requires a single-dose container, tighter aseptic processing, and more disciplined discard procedures. For this drug, the commercial case for preservative-free packaging is stronger than the case for adding a novel preservative system.
What formulation patents protect succinylcholine chloride?
There is no evident current U.S. patent barrier that materially protects the succinylcholine chloride active ingredient or its basic aqueous injectable formulation. Succinylcholine chloride has been used clinically for decades, and the principal composition and use concepts are long-established.
Patent and exclusivity position
| Category |
Current commercial significance |
| Active-ingredient patent |
No live U.S. composition-of-matter barrier expected |
| Basic aqueous injection patent |
No material modern barrier identified |
| Formulation patent |
Potentially relevant only for a genuinely differentiated system |
| Method-of-use patent |
Limited value because core anesthesia and intubation uses are established |
| Orange Book listed patent |
No material patent estate expected to block standard generic injection entry |
| FDA new chemical entity exclusivity |
Expired |
| Generic Paragraph IV exposure |
Low for the basic product because blocking patents are not central |
| Biosimilar exposure |
Not applicable |
A new applicant could seek patents on a specific prefilled syringe, container-closure configuration, stability-enhancing formulation, manufacturing process, or device combination. Such claims would need meaningful technical distinction. A patent directed only to conventional water, sodium chloride, pH adjustment, and standard vial packaging would face substantial validity and obviousness pressure.
The commercial protection strategy should therefore focus on product differentiation and supply performance, not on broad patent claims covering the drug itself.
When does succinylcholine chloride lose exclusivity?
Succinylcholine chloride lost practical market exclusivity many years ago. The product is a mature generic injectable, and FDA approval pathways are primarily abbreviated applications or other generic-drug routes rather than new-drug exclusivity strategies.
No meaningful branded exclusivity timeline remains for the active ingredient. Commercial entry is governed by:
- FDA approval of the applicant’s specific strength and presentation.
- Manufacturing capacity and sterile-fill readiness.
- Drug-shortage conditions.
- Hospital contracting and group-purchasing organization access.
- Product reliability, back-order history, and substitution policies.
The absence of patent exclusivity does not eliminate launch risk. Sterile injectables can face substantial regulatory and operational barriers because of validation, aseptic processing, container integrity, stability, and supply-chain requirements.
What is the Orange Book status of succinylcholine chloride?
The Orange Book is relevant for reference-listed products and approved therapeutic equivalents, but the practical Orange Book issue for succinylcholine chloride is not patent blocking. The product is a mature injectable with generic competition and no apparent active-ingredient patent estate that would support a conventional Paragraph IV litigation campaign. (FDA, 2024)
An applicant should assess:
- The exact reference-listed drug for each strength
- Therapeutic-equivalence coding
- Whether the proposed product is single-dose or multidose
- Preservative content
- Container size and dosage concentration
- Any current listed patent or exclusivity entry associated with the selected reference product
- FDA product-specific guidance and prior approval history
The 20 mg/mL and 100 mg/mL presentations should be treated as separate commercial products. The higher concentration reduces injection volume but creates a greater risk of dosing confusion. Packaging and labeling must make the concentration distinction conspicuous.
Which companies are challenging or competing with succinylcholine chloride?
Competition is primarily from generic injectable manufacturers and from alternative neuromuscular blockers rather than from patent challengers.
Direct competitors
Direct competitors include manufacturers marketing generic succinylcholine chloride injection and branded or legacy products such as Quelicin and Anectine-associated presentations. Supplier availability can change because injectable products are frequently affected by manufacturing interruptions and temporary shortages. FDA drug-shortage records and current labeling should be used for live supplier confirmation. (FDA, 2024b)
Therapeutic competitors
| Product |
Class |
Commercial advantage |
| Succinylcholine chloride |
Depolarizing neuromuscular blocker |
Very rapid onset and short duration |
| Rocuronium bromide |
Nondepolarizing neuromuscular blocker |
Longer duration; commonly used for rapid-sequence intubation |
| Vecuronium bromide |
Nondepolarizing neuromuscular blocker |
Controlled duration in anesthesia |
| Atracurium and cisatracurium |
Nondepolarizing neuromuscular blockers |
Use in selected anesthesia and critical-care settings |
Rocuronium is the principal clinical substitute in many rapid-sequence intubation protocols, particularly where succinylcholine contraindications are present. Succinylcholine retains a role where clinicians value short duration, rapid onset, low acquisition cost, and established emergency-airway familiarity.
What excipient strategy offers the best commercial opportunity?
Preservative-free single-dose vial
This is the most straightforward opportunity. A 20 mg/mL single-dose vial can target operating rooms, emergency departments, pediatric hospitals, and anesthesia medication trays. The product should minimize preparation steps and use a familiar vial size compatible with automated dispensing systems.
Preservative-free prefilled syringe
A prefilled syringe can reduce preparation time and drawing errors during emergency airway management. The opportunity is stronger where hospitals have standardized rapid-sequence intubation kits or preassembled emergency carts.
The technical program would require assessment of:
- Syringe material
- Stopper and plunger compatibility
- Siliconization
- Extractables and leachables
- Drug adsorption
- Sterility assurance
- Dose accuracy
- Needle-free connector compatibility
- Stability across refrigerated and permitted room-temperature excursions
A prefilled syringe may obtain device or packaging patent protection, but the primary commercial moat would be workflow integration and contracting.
Two-concentration portfolio
A manufacturer could offer:
- 20 mg/mL for conventional weight-based dosing and pediatric or lower-volume administration
- 100 mg/mL for high-volume adult emergency and operating-room use
The portfolio should use clearly differentiated labels, cap colors, carton graphics, and barcode identifiers. The 100 mg/mL concentration has a higher wrong-dose risk because a small volume contains a clinically significant amount of drug.
Room-temperature excursion strategy
Refrigeration can create inventory and emergency-cart constraints. A product with validated room-temperature excursion stability could reduce wastage and simplify distribution. This would require real-time and accelerated stability data, photostability testing, container-closure studies, and a label-supported excursion period.
A room-temperature product would have meaningful commercial value even without patent protection because hospitals can reduce discard rates and improve emergency availability.
Multidose vial with preservative
A multidose vial may reduce packaging cost and support high-volume operating-room use. Benzyl alcohol, however, limits pediatric positioning and can complicate formulary decisions. A multidose product is commercially rational only where the target institution has predictable turnover and defined in-use handling procedures.
What manufacturing and intellectual-property barriers affect entry?
The primary barriers are sterile-manufacturing and supply-chain barriers.
Manufacturing requirements
A viable commercial program must control:
- Raw-material identity and impurity profile
- Bioburden and endotoxin
- Sterile filtration or terminal sterilization strategy
- Aseptic filling
- Container-closure integrity
- Particulate matter
- Extractables and leachables
- pH and osmolality
- Assay and degradation products
- Cold-chain distribution
- Product-specific in-use stability
Succinylcholine chloride can degrade under unfavorable conditions, and packaging, temperature, light exposure, and solution pH must be evaluated together. A formulation that appears simple still requires a robust stability package.
Intellectual-property barriers
Relevant patent opportunities may exist around:
- Prefilled delivery systems
- Emergency-cart packaging
- Concentration-specific labeling systems
- Stable room-temperature formulations
- Novel container-closure systems
- Automated dispensing compatibility
- Combination products with airway or anesthesia devices
Broad claims directed to the active ingredient or conventional injectable composition are unlikely to provide durable protection. Narrow patents can support differentiation but will not replace reliable supply and FDA-compliant manufacturing.
What litigation and settlement risks affect succinylcholine chloride?
Paragraph IV litigation risk is limited because the mature active ingredient does not depend on a significant current patent estate. The more relevant legal risks are:
- Product-liability claims involving hyperkalemia, malignant hyperthermia, or prolonged paralysis
- Medication-error claims involving 20 mg/mL and 100 mg/mL products
- Preservative exposure and pediatric labeling issues
- Manufacturing-defect claims
- Container-closure failures
- False or overstated stability claims
- Trade dress and packaging-copying disputes
Settlement agreements are not central to the market structure in the same way they are for newer branded medicines. A generic entrant is more likely to compete through approval timing, contract pricing, and supply reliability than through a patent settlement.
What generic launch scenarios exist for succinylcholine chloride?
Low-cost vial launch
The applicant launches a standard refrigerated vial in one concentration. This has the lowest development cost but limited differentiation and high exposure to price competition.
Dual-strength hospital portfolio
The applicant launches 20 mg/mL and 100 mg/mL presentations with standardized packaging. This improves contracting potential but increases validation, inventory, and medication-safety requirements.
Premium preservative-free launch
The applicant targets pediatric hospitals and high-acuity institutions with single-dose, preservative-free products. Pricing may be stronger if supply reliability and availability solve a formulary problem.
Prefilled emergency product
The applicant offers a ready-to-administer syringe. This has the highest packaging and device-development burden but may create the strongest hospital workflow differentiation.
Supply-resilience strategy
The applicant contracts redundant API sources, maintains qualified alternate fill-finish capacity, and uses conservative inventory levels. In a mature injectable market, supply continuity can be more valuable than a modest formulation improvement.
How strong is the patent estate for succinylcholine chloride?
The patent estate is weak for the active ingredient and conventional injection. It is potentially moderate for narrowly defined delivery, packaging, stability, or device innovations, provided those innovations are technically meaningful and supported by comparative data.
| Asset type |
Patent strength |
Commercial usefulness |
| Succinylcholine chloride molecule |
Very low |
No practical exclusivity |
| Conventional aqueous injection |
Low |
Limited blocking value |
| Preservative-free formulation |
Low to moderate |
Useful only with a specific technical distinction |
| Room-temperature stability |
Moderate if supported by nonobvious data |
Potential supply and waste advantage |
| Prefilled syringe |
Moderate |
Workflow and packaging differentiation |
| Medication-error-resistant packaging |
Moderate |
Hospital contracting value |
| Manufacturing process |
Moderate |
Difficult to enforce against independent processes |
| Method of use |
Low |
Core indications are established |
What is the commercial outlook for succinylcholine chloride?
Revenue exposure is tied to procedure volume, hospital purchasing, product availability, and generic price pressure. The market is mature, and standard vial products are likely to face commoditization. The most defensible commercial opportunities are products that reduce hospital labor, prevent wrong-concentration errors, improve pediatric suitability, or remain available during competitor shortages.
A manufacturer should prioritize a preservative-free 20 mg/mL product, followed by a clearly differentiated 100 mg/mL presentation. A prefilled syringe is a higher-value option for institutions with emergency-airway standardization. A novel excipient is unlikely to generate sufficient value to justify added regulatory complexity unless it solves a documented stability or packaging problem.
Key Takeaways
- Succinylcholine chloride has no meaningful remaining active-ingredient exclusivity.
- The basic aqueous injection is a low-patent, mature generic product.
- Preservative-free single-dose packaging is the most practical excipient and formulation opportunity.
- Benzyl alcohol can support multidose use but weakens pediatric and neonatal positioning.
- Room-temperature excursion stability could reduce hospital waste and improve emergency availability.
- The 20 mg/mL and 100 mg/mL strengths should be commercialized with strong visual differentiation.
- Prefilled syringes can create workflow value but require substantial device and compatibility development.
- Sterile manufacturing, container integrity, and supply continuity are greater barriers than patent litigation.
- Rocuronium is the principal therapeutic competitor in rapid-sequence intubation.
- A successful launch strategy should compete on availability, safety-oriented packaging, and institutional workflow rather than on molecule-level IP.
FAQs
Can succinylcholine chloride be reformulated with a novel preservative?
Yes, but the commercial rationale is limited. A novel preservative would require injectable safety, compatibility, antimicrobial-effectiveness, extractables, leachables, and stability data. Preservative-free packaging is generally more attractive for pediatric and emergency-hospital positioning.
Is succinylcholine chloride suitable for a ready-to-use autoinjector?
The product could be incorporated into a specialized delivery system, but an autoinjector would face dose-volume, route, emergency-use, and human-factors constraints. A prefilled syringe is more commercially plausible for hospital airway-management workflows.
Does succinylcholine chloride require a biosimilar strategy?
No. Succinylcholine chloride is a chemically synthesized small molecule, not a biologic. Biosimilar pathways and biosimilar interchangeability rules do not apply.
Can a manufacturer obtain patent protection for a succinylcholine chloride formulation?
Potentially, but protection would need to rest on a specific, nonobvious formulation or delivery improvement. Conventional excipient combinations and ordinary vial presentations are unlikely to support strong exclusionary rights.
Which presentation has the best hospital purchasing potential?
A preservative-free, single-dose, 20 mg/mL vial has the broadest institutional applicability. A 100 mg/mL vial and a prefilled syringe can expand the portfolio where emergency-airway demand and medication-safety programs justify the added complexity.
References
-
DailyMed. (2024a). Succinylcholine chloride injection prescribing information. U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/
-
U.S. Food and Drug Administration. (2023a). Quelicin: Succinylcholine chloride injection prescribing information. https://www.accessdata.fda.gov/
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/
-
U.S. Food and Drug Administration. (2024b). Drug shortages database. https://www.accessdata.fda.gov/scripts/drugshortages/
-
U.S. Food and Drug Administration. (2024c). Inactive ingredient database. https://www.accessdata.fda.gov/scripts/cder/iig/index.cfm
